Peculiarities of Styfimol impact on carbohydrate, lipid metabolism and blood adipokine levels in patients with type 2 diabetes with obesity and arterial hypertension

Background. The purpose of the study was to eva­luate the impact of treatment with a fixed combination of the extract of garcinia cambogia 0.1 g (equivalent to hydroxycitric acid 0.05 g), chromium picolinate 0.0001 g, L­tyrosine 0.5 g, L­carnitine 0.015 g, dried brown algae extract (Fucus vesiculosus L.) equivalent to iodine 0.037 mg on lipid and carbohydrate metabolism, as well as on the level of adipokines (leptin and adiponectin) in the blood of type 2 diabetes patients with obesity and arterial hypertension. Materials and methods. The study included 53 patients (of whom 25 were men) aged 55.90 ± 2.15 years with type 2 diabetes, hypertension and obesity (body mass index ≥ 30 kg/m 2 ). Results. In the main group (n = 30), after 12 weeks of treatment with such a fixed combination of 1 capsule 3 times daily, the HbA1c level decreased by 0.87 ± 0.14 % (P 1  = 0.0001), in the control group (n = 23) — by 0.17 ± 0.16 % (P 1 = 0.1), the difference between the main and control groups was statistically significant (P 2 = 0.001). The level of fasting plasma glucose in the main group reduced by 8.00 ± 4.26 % (P 1  = 0.03), in the control group — by 2.7 ± 4.8 % (P 1 = 0.2), the difference between the groups was statistically non­significant (P 2  = 0.4). The level of low­density lipoproteins in the main group decreased by 18.20 ± 5.43 % (P 1 = 0.001), in the control group — increased by 6.9 ± 6.2 % (P 1 = 0.7), the difference between the groups was statistically significant (P 2 = 0.003). In the main group, there was a reduction in triglyceride levels by 14.9 ± 6.5 % (P 1 = 0.02), in the control group — an increase by 20.30 ± 7.46 % (P 1 = 0.04), the difference between the groups was statistically significant (P 2 = 0.008). In the main group, the level of high­density lipoproteins increased by 20.2 ± 6.8 % (P 1 = 0.03), in the control group — decreased by 3.7 ± 7.7 % (P 1 = 0.12), the difference between the groups was statistically significant (P 2 = 0.02). Therapy with the study drug did not affect insulin resistance, which was determined by the НOMA­IR, and the level of plasma fasting insulin. Therapy with the study drug showed a decrease in leptin levels by 21.4 ± 6.1 % (P 1 = 0.004), and a tendency to increase in adiponectin levels by 19.30 ± 9.36 % (P 1 = 0.39). Conclusions. The reduction in body weight on the background of study drug therapy led to an improvement in carbohydrate and lipid metabolism, and also had a positive effect on leptin levels in the blood plasma.